Harmony Biosciences (HRMY) Q2 FY26 earnings call

Harmony Biosciences reported a defining quarter with record WAKIX revenue, firmly on track to exceed $1 billion for the year, driven by strong patient additions. The company also unveiled encouraging Phase I data for its potential best-in-class orexin-2 agonist, BP-205, with multiple data catalysts expected over the next six months. Harmony maintains a strong balance sheet and is actively pursuing strategic business development opportunities while protecting its pitolisant franchise IP.